Cholestatic Pruritus Market Size Forecasted to Reach USD 2.55 Billion by 2035

According to Precedence Research, the global cholestatic pruritus market size will grow from USD 1.40 billion in 2025 to nearly USD 2.55 billion by 2035, expanding at a CAGR of 6.20% from 2026 to 2035. This growth is fueled by an increased focus on novel therapeutic options, enhanced diagnostic tools, and a rise in healthcare awareness.

AI's Role in the Cholestatic Pruritus Market

Artificial intelligence (AI) is increasingly playing a crucial role in the cholestatic pruritus market. With its ability to analyze vast amounts of medical data, AI is helping to identify new biomarkers, predict patient responses to treatments, and even aid in drug discovery. AI-driven diagnostic tools are being developed to more accurately detect the underlying causes of cholestatic pruritus, allowing for earlier interventions and personalized treatments. Additionally, AI is accelerating the development of targeted therapies, further enhancing the efficiency of treatments available to patients.

Moreover, AI-powered solutions are optimizing drug development pipelines by predicting the effectiveness of new drugs and identifying potential side effects before clinical trials. This promises not only faster regulatory approvals but also more precise treatments, which could significantly improve patient outcomes in the coming years.

The Full Study is Readily Available 📥 Download Sample Pages of the Report 👉 https://www.precedenceresearch.com/sample/8320

Cholestatic Pruritus Market Key Growth Drivers

🔹 Rising Liver Disease Prevalence: Increasing cases of chronic liver conditions like PBC, PSC, and ICP are boosting the demand for cholestatic pruritus treatments.

🔹 Advances in Targeted Treatments: The shift towards targeted therapies such as IBAT inhibitors provides significant relief from chronic itching, marking a turning point in disease management.

🔹 Healthcare Advancements: Enhanced diagnostic methods and the growing accessibility of healthcare facilities, particularly in regions like North America and Europe, are major factors driving the market.

🔗 Power Your Strategy with Full Market Data 👉 https://www.precedenceresearch.com/cholestatic-pruritus-market

Cholestatic Pruritus Market Opportunities

Targeted Therapy Development: With increasing investment in R&D for targeted treatments, there is a substantial opportunity for the market to grow. The development of novel antipruritic drugs and bile acid modulators is expected to significantly expand market potential.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Cholestatic Pruritus Market Trends

The cholestatic pruritus market is experiencing several transformative trends that are shaping the landscape. The shift from traditional treatments to more targeted therapies, like IBAT inhibitors such as odevixibat and maralixibat, is one of the key drivers of market growth. These treatments effectively target the root cause of itching by reducing bile acid accumulation.

Additionally, the market is witnessing heightened research into pediatric liver diseases, such as Alagille syndrome, and the development of therapies aimed at improving patients' quality of life by addressing the debilitating symptoms of chronic itching associated with liver dysfunctions like PBC and PSC.

Moreover, the increasing use of genetic testing and advanced diagnostic technologies, along with rising healthcare awareness, is expected to further support market growth as more patients are accurately diagnosed and treated.

Cholestatic Pruritus Market Size and Forecasts

🔹 Market size in 2025: USD 1.40 Billion
🔹 Market size in 2026: USD 1.49 Billion
🔹 Market size by 2035: USD 2.55 Billion
🔹 CAGR: 6.20% (2026-2035)
🔹 Forecast period: 2026-2035
🔹 Base year: 2025

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8320

Cholestatic Pruritus Market Regional Insights

North America currently holds the largest share of the market at 35%, driven by high disease prevalence, advanced healthcare infrastructure, and the adoption of new therapies. The U.S., in particular, is leading the charge with the availability of FDA-approved drugs and a well-established healthcare system.

Asia Pacific is the fastest-growing region for cholestatic pruritus, with a projected growth rate fueled by rising healthcare investments, government support for novel drug approvals, and an increase in liver disease cases in countries like China and India.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8320

Cholestatic Pruritus Market Segmentation

🔹 Treatment Type Insights

The pharmacological treatments segment dominated the cholestatic pruritus market in 2025 with a 75% share. This dominance is driven by the complex disease mechanism, which requires targeted systemic therapy to control pruritogenic substances. Clinical guidelines from bodies like EASL and AASLD further reinforce the use of drug-based interventions, strengthening market demand.

Non-pharmacological treatments are the second-largest segment and are expected to grow steadily from 2026 to 2035. Their growth is supported by cases where patients do not respond well to drugs or experience adverse effects. Options like UVB phototherapy and liver transplantation offer safer alternatives, especially for advanced liver disease and pregnancy-related cholestasis.

🔹 Disease Type Insights

Primary Biliary Cholangitis (PBC) led the market with a 60% share in 2025, as it is a major cause of chronic cholestasis in adults. A large proportion of patients experience severe pruritus, creating strong unmet medical needs. Increasing awareness, higher diagnosis rates, and regulatory approvals such as linerixibat (FDA, 2026) are driving market growth.

Cholestasis with Hepatic Failure segment is growing due to the high burden of pruritus in liver failure patients. There is strong demand for therapies that can reduce bile acids while improving liver function, offering both symptom relief and disease management benefits.

Primary Sclerosing Cholangitis (PSC) accounted for about 15% share in 2025. It is associated with severe chronic itching, often leading to sleep disorders, depression, and in advanced cases, liver transplantation. Its association with younger patients and inflammatory bowel disease further increases treatment demand.

🔹 End Use Insights

Hospitals dominated the market with a 50% share in 2025 due to the severity of cholestatic pruritus and the need for multidisciplinary care. Complex cases require hepatologists, dermatologists, and continuous monitoring, making hospitals the primary treatment setting.

Clinics are the second-largest segment and are expected to grow significantly. They provide structured, stepwise management and are increasingly involved in delivering newer, targeted therapies that require specialist supervision.

Ambulatory Surgical Centers (ASCs) held a 10% share in 2025 and are gaining traction due to cost efficiency and convenience. They support outpatient procedures such as diagnostics and infusions, reducing the need for hospital stays.

Home care also accounted for 10% of the market. Growth is driven by oral therapies, improved quality-of-life focus, and digital health tools that enable remote monitoring and symptom management.

Cholestatic Pruritus Market Key Players

➢ Allergan
➢ Mundipharma
➢ Intercept Pharmaceuticals
➢ Eisai Co., Ltd.
➢ Gilead Sciences
➢ Novartis AG
➢ Zydus Cadila
➢ AbbVie Inc.
➢ Bristol-Myers Squibb
➢ Johnson & Johnson
➢ Amgen Inc.
➢ Pfizer Inc.
➢ Lilly
➢ Orphazyme
➢ Takeda Pharmaceuticals

Recent Updates

🔸 March 2026: The U.S. FDA approved Lynavoy (Linerixibat) for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). This approval marked a significant step in addressing the unmet need for effective treatments.

🔸 November 2025: Maralixibat received approval for treating cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8320

Segments Covered in the Report

🔸 By Treatment Type

Pharmacological Treatments
Ursodeoxycholic Acid (UDCA)
Antihistamines
Opioid Antagonists
Glucocorticoids
Topical Steroids
Others
Non-pharmacological Treatments
Phototherapy
Plasmapheresis
Liver Transplantation

🔸 By Disease Type

Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Cholestasis due to Hepatic Failure
Others

🔸 By End-Use

Hospitals
Clinics
Ambulatory Surgery Centres
Homecare Settings

🔸 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.